You are here

Article Text

Article menu
Download PDFPDF
Prognosis
Excess mortality after HIV seroconversion has greatly decreased in the past 10 years

https://doi.org/10.1136/ebn.12.1.26

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    K Porter

    Dr K Porter, MRC Clinical Trials Unit, London, UK; kp@ctu.mrc.ac.uk

    QUESTIONS

    What is the risk of death in HIV-infected people compared with the general population? Has this risk changed since the introduction of highly active antiretroviral therapy (HAART)?

    METHODS

    Design:

    inception cohort followed up for a median 6.3 years.

    Setting:

    10 European countries, Australia, and Canada.

    Patients:

    16 534 patients ⩾15 years of age at HIV seroconversion (median age 29 y, 78% men) who had well-estimated dates of seroconversion (within 18 mo) and exposure to HIV through injection drug use (18% of patients), sex between men (57%), or heterosexual sex (24%).

    Prognostic factors:

    calendar period of follow-up (before 1996, 1996–7, 1998–9, 2000–1, 2002–3, and 2004–6), sex, age at seroconversion, and HIV exposure category.

    Outcomes:

    mortality, excess …

    View Full Text

    Footnotes

    • Source of funding: European Union.